Outpatient cross-titration to buprenorphine for chronic pain: A retrospective analysis.

Q3 Medicine
Satoru Ito, Mackenzie Welsh, Christina Bockman, Rebecca Dale, David Pilkington, Katherin Peperzak
{"title":"Outpatient cross-titration to buprenorphine for chronic pain: A retrospective analysis.","authors":"Satoru Ito, Mackenzie Welsh, Christina Bockman, Rebecca Dale, David Pilkington, Katherin Peperzak","doi":"10.5055/jom.0839","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To determine the effectiveness and safety of the University of Washington's buprenorphine cross-titration protocol for chronic pain in the outpatient setting.</p><p><strong>Methods: </strong>Retrospective chart review was performed on 150 patients transitioned from full µ-opioid agonist therapy to buprenorphine using the University of Washington Medical Center Pain Clinic's cross-titration protocol between September 1, 2020, and December 31, 2021, in an outpatient setting. Primary outcome was to determine the percentage of patients who completed the cross-titration and continued buprenorphine without full µ-opioid agonists 4 weeks after completion. Secondary outcomes included final buprenorphine dose, days needed to complete cross-titration, deviation rates from the protocol, and opioid-related adverse events.</p><p><strong>Results: </strong>Fifteen of 31 (48.4 percent) included patients successfully converted to buprenorphine. Median duration of successful cross-titration was 29 days (interquartile range 19-57). Average end-titration dose for patients on buprenorphine/naloxone sublingual films was 7.9 ± 5.7 mg/day, while for buprenorphine transdermal (TD) patches, it was 11.9 ± 4.8 mcg/h. Morphine equivalent daily dose (MEDD) prior to induction varied widely. All patients transitioned to TD buprenorphine were taking ≤30 mg MEDD. Patients previously taking >120 mg MEDD stabilized on 8-16 mg/day buprenorphine. Most common reasons for cross-titration failure were inadequate pain control and intolerable adverse effects.</p><p><strong>Discussion: </strong>The University of Washington's buprenorphine cross-titration protocol for chronic pain was successful in about half of included patients undergoing conversion from chronic full µ-opioid agonist therapy and generally well tolerated. Clinical responses were widely variable, and many required slower taper and higher end-titration buprenorphine dose than anticipated. Although protocols provide structure for cross-titration, each course should be monitored closely and individualized.</p>","PeriodicalId":16601,"journal":{"name":"Journal of opioid management","volume":"19 6","pages":"543-554"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of opioid management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5055/jom.0839","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To determine the effectiveness and safety of the University of Washington's buprenorphine cross-titration protocol for chronic pain in the outpatient setting.

Methods: Retrospective chart review was performed on 150 patients transitioned from full µ-opioid agonist therapy to buprenorphine using the University of Washington Medical Center Pain Clinic's cross-titration protocol between September 1, 2020, and December 31, 2021, in an outpatient setting. Primary outcome was to determine the percentage of patients who completed the cross-titration and continued buprenorphine without full µ-opioid agonists 4 weeks after completion. Secondary outcomes included final buprenorphine dose, days needed to complete cross-titration, deviation rates from the protocol, and opioid-related adverse events.

Results: Fifteen of 31 (48.4 percent) included patients successfully converted to buprenorphine. Median duration of successful cross-titration was 29 days (interquartile range 19-57). Average end-titration dose for patients on buprenorphine/naloxone sublingual films was 7.9 ± 5.7 mg/day, while for buprenorphine transdermal (TD) patches, it was 11.9 ± 4.8 mcg/h. Morphine equivalent daily dose (MEDD) prior to induction varied widely. All patients transitioned to TD buprenorphine were taking ≤30 mg MEDD. Patients previously taking >120 mg MEDD stabilized on 8-16 mg/day buprenorphine. Most common reasons for cross-titration failure were inadequate pain control and intolerable adverse effects.

Discussion: The University of Washington's buprenorphine cross-titration protocol for chronic pain was successful in about half of included patients undergoing conversion from chronic full µ-opioid agonist therapy and generally well tolerated. Clinical responses were widely variable, and many required slower taper and higher end-titration buprenorphine dose than anticipated. Although protocols provide structure for cross-titration, each course should be monitored closely and individualized.

门诊病人交叉滴注丁丙诺啡治疗慢性疼痛:回顾性分析。
目的:确定华盛顿大学丁丙诺啡交叉滴注方案在门诊治疗慢性疼痛的有效性和安全性:确定华盛顿大学门诊慢性疼痛丁丙诺啡交叉滴定方案的有效性和安全性:在 2020 年 9 月 1 日至 2021 年 12 月 31 日期间,对门诊环境中使用华盛顿大学医学中心疼痛诊所的交叉滴定方案从完全μ-阿片激动剂治疗过渡到丁丙诺啡的 150 名患者进行了回顾性病历审查。主要结果是确定完成交叉滴注并在完成后 4 周继续服用丁丙诺啡而未服用全量 µ 类阿片激动剂的患者比例。次要结果包括最终丁丙诺啡剂量、完成交叉滴注所需天数、偏离方案率以及阿片类药物相关不良事件:31名患者中有15名(48.4%)成功转用丁丙诺啡。成功交叉滴定的中位持续时间为 29 天(四分位间范围为 19-57)。丁丙诺啡/纳洛酮舌下含片患者的平均最终剂量为 7.9 ± 5.7 毫克/天,而丁丙诺啡透皮(TD)贴剂的平均最终剂量为 11.9 ± 4.8 微克/小时。诱导前的吗啡当量日剂量(MEDD)差异很大。所有过渡到 TD 丁丙诺啡的患者的 MEDD 均小于 30 毫克。之前服用 >120 毫克 MEDD 的患者稳定服用 8-16 毫克/天的丁丙诺啡。交叉滴定失败的最常见原因是疼痛控制不足和无法忍受的不良反应:讨论:华盛顿大学的丁丙诺啡慢性疼痛交叉滴注方案在约半数从慢性全µ-阿片激动剂治疗转换而来的患者中取得了成功,并且普遍耐受性良好。临床反应差异很大,许多患者需要比预期更慢的减量速度和更高的丁丙诺啡最终剂量。虽然方案提供了交叉滴定的结构,但每个疗程都应进行密切监测并因人而异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of opioid management
Journal of opioid management Medicine-Anesthesiology and Pain Medicine
CiteScore
1.00
自引率
0.00%
发文量
54
期刊介绍: The Journal of Opioid Management deals with all aspects of opioids. From basic science, pre-clinical, clinical, abuse, compliance and addiction medicine, the journal provides and unbiased forum for researchers and clinicians to explore and manage the complexities of opioid prescription.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信